In OSA patients without pre-existing cardiovascular disease, MADs reduced the NT-proBNP concentration, suggesting that it might alleviate the cardiac strain associated with OSA, whereas CPAP showed no significant improvement, with NT-proBNP levels slightly increasing, implying MADs might better reduce subclinical cardiovascular stress in certain patients [27]. The gene discussed is NPPB; the disease is obstructive sleep apnea syndrome.